Prof.Giulia Pinton| preclinical | Best Paper Award
Prof, Giulia Pintoni, University of Piemonte Orientale, Italy.
Prof. Giulia Pintoni is a distinguished faculty member at the University of Piemonte Orientale in Italy, where she specializes in . With a focus on [specific topics of interest or research], Prof. Pintoni has published numerous articles in leading academic journals and has contributed to various conferences both nationally and internationally. She is known for her engaging teaching style and commitment to mentoring students, fostering a collaborative learning environment. In addition to her academic pursuits, she actively participates in community outreach initiatives that promote .
Summary:
Prof. Giulia Pinton is a distinguished researcher in the field of cancer biology, with a specific emphasis on mesothelioma. Her educational background and extensive research experience provide a strong foundation for her contributions to the scientific community. Through her leadership in various research projects and her role in mentoring, she has made a significant impact both academically and professionally.
🎓 Education :
PhD in Food and Pharmaceutical Biotechnologies,January 2011, University of Piemonte Orientale, Italy, Supervised by: Prof. Laura Morom, Dissertation Title: “Estrogen receptor beta exerts tumor repressive functions in Human Malignant Pleural Mesothelioma.”Visiting PhD Student, January 2009 – June 2009. Molecular Medicine Lab, Royal College of Surgeons, Dublin, Ireland, Supervised by: Prof. B.J. Harvey and Dr. Warren Thomas.,Master Degree in Medical Biotechnologies,October 2006
University of Piemonte Orientale, Novara, Italy.,Degree in Biotechnology,November 2004,University of Piemonte Orientale, Novara, Italy.
🏢 Experience:
Associate ProfessorDecember 2022 – Present,Department of Pharmaceutical Sciences, University of Piemonte Orientale
Academic Discipline: BIOS10/A, Cellular and Experimental Biology.Fixed-Term Research AssistantDecember 2019 – November 2022Department of Pharmaceutical Sciences, University of Piemonte Orientale
Academic Discipline: BIO/13, Cellular and Experimental Biology.Postdoctoral ResearcherSeptember 2017 – January 2019Department of Pharmaceutical Sciences, University of Piemonte Orientale.Contract Professor of Applied BiologyOctober 2016 – February 2017Master’s degree in Biology, University of Piemonte Orientale.Postdoctoral ResearcherFebruary 2011 – April 2016Department of Pharmaceutical Sciences, University of Piemonte Orientale.
Research Focus :
Dr. Giulia Pinton’s research centers on preclinical in vitro and in vivo studies aimed at validating novel biomarkers and therapeutic targets in cancer, with a specific emphasis on mesothelioma. Her expertise encompasses the interplay between signaling pathways, receptor-mediated pathways, metabolic alterations, and epigenetics, focusing on their roles in cell proliferation, senescence, stemness, and drug resistance mechanisms. Dr. Pinton has successfully supervised undergraduate and postgraduate students, fostering teamwork, problem-solving skills, and project management capabilities.
🔬Awards:
Best Oral Presentation, AIBG Trento, 2010Career breaks, Maternity leave (year 2017, Maternity leave (year 2021)
Conclusion:
Prof. Pinton’s dedication to advancing cancer research, her innovative approach to understanding complex biological mechanisms, and her active engagement in academia position her as a strong candidate for the Research for Best Paper Award. By addressing the areas for improvement, particularly in publication volume and public engagement, she can further enhance her influence in the field. Overall, her work holds promise for significant advancements in therapeutic strategies against cancer, making her a worthy recipient of this award.
Publications :
- Brunelli E, Pinton G, Chianale F, Graziani A, Appendino G, Moro L. 8-Prenylnaringenin inhibits epidermal growth factor-induced MCF-7 breast cancer cell proliferation by targeting phosphatidylinositol-3-OH kinase activity. J Steroid Biochem. 2009; 113:163-170.
- Brunelli E, Pinton G, Bellini P, Minassi A, Appendino G, Moro L. Flavonoid-induced autophagy in hormone sensitive breast cancer cells. Fitoterapia. 2009; 80(6):327-332.
- Pinton G, Brunelli E, Murer B, Puntoni R, Puntoni M, Fennell DA, Gaudino G, Mutti L, Moro L. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res. 2009; 69(11):4598-4604.
- Pinton G, Thomas W, Bellini P, Manente AG, Favoni RE, Harvey BJ, Mutti L, Moro L. Estrogen receptor exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to Gefitinib. PLoS One. 2010; 5(11): e14110.
- Manente AG, Pinton G, Tavian D, Lopez-Rodas G, Brunelli E, Moro L. Coordinated sumoylation and ubiquitination modulate EGF induced EGR1 expression and stability. PLoS One. 2011; 5(11): e14110.
- Pinton G, Manente AG, Angeli G, Mutti L, Moro L. Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma. PLoS One. 2012; 7(5): e36856.
- Pinton G, Manente AG, Moro L, Mutti L. Circulating tumor cells as a diagnostic test for malignant pleural mesothelioma. Expert Opin Med Diagn. 2012; 6(3):171-177.
- Pinton G, Manente AG, Murer B, De Marino E, Mutti L, Moro L. PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1. J Cell Mol Med. 2013; 17(2):233-241.
- Pinton G, Manente AG, Tavian D, Moro L, Mutti L. Therapies currently in Phase II trials for malignant pleural mesothelioma. Expert Opin Investig Drugs. 2013; 22(10):1255-1263.
- Manente AG, Valenti D, Pinton G, Jithesh PV, Daga A, Rossi L, Gray SG, O’Byrne KJ, Fennell DA, Vacca RA, Nilsson S, Mutti L, Moro L. Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo. Oncogenesis. 2013; 2
- Pinton G, Manente AG, Daga A, Cilli M, Rinaldi M, Nilsson S, Moro L. Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity. Mol Cancer. 2014; 13:227.
- Manente AG*, Pinton G*, Zonca S, Cilli M, Rinaldi M, Daga A, Nilsson S, Moro L. Intracellular lactate-mediated induction of estrogen receptor beta (ERβ) in biphasic malignant pleural mesothelioma cells. Oncotarget. 2015; 6(28):25121-34. (*The authors contribute equally to the work.)
- Pinton G, Zonca S, Manente AG, Cavaletto M, Borroni E, Daga A, Jithesh PV, Fennell D, Nilsson S, Moro L. SIRT1 at the crossroads of AKT1 and ERβ in malignant pleural mesothelioma cells. Oncotarget. 2016; 7(12):14366-14379.
- Manente AG*, Pinton G*, Zonca S, Tavian D, Habib T, Jithesh PV, Fennell D, Nilsson S, Moro L. KDM6B histone demethylase is an epigenetic regulator of estrogen receptor β expression in human pleural mesothelioma. Epigenomics. 2016; 8(9):1227-1238. (*The authors contribute equally to the work.)
- Zonca S, Pinton G, Wang Z, Soluri MF, Tavian D, Griffin M, Sblattero D, Moro L. Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia. Cell Death Dis. 2017; 8(2)